Literature DB >> 9060002

Can epitope-focused vaccines select advantageous immune responses?

P J Delves1, T Lund, I M Roitt.   

Abstract

One of the great success stories of preventive medicine is the achievement of protection against many pathogens by the simple procedure of vaccination. The rationale behind vaccination is to generate a protective immune response and an expanded population of memory cells ready to encounter the infectious agent, which will then elicit a potent secondary immune response. However, the development of effective vaccines against many pathogens has, so far, been unsuccessful. Many vaccines in current use fail to direct the immune response towards the epitopes that will ensure optimal protection. In these circumstances, can vaccines be produced that focus the immune system in a calculated, epitope-specific manner?

Mesh：

Substances：

Year:  1997        PMID： 9060002     DOI： 10.1016/s1357-4310(96)20036-x

Source DB:  PubMed          Journal:  Mol Med Today        ISSN： 1357-4310


  10 in total

1.  Refocusing of B-cell responses following a single amino acid substitution in an antigen.

Authors:  M D Chiesa; P M Martensen; C Simmons; N Porakishvili; J Justesen; G Dougan; I M Roitt; P J Delves; T Lund
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

4.  Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Authors:  Timothy Cardozo; Shixia Wang; Xunqing Jiang; Xiang-Peng Kong; Catarina Hioe; Chavdar Krachmarov
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

5.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

6.  A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: evidence for recombination within and between species.

Authors:  K Poulsen; J Reinholdt; C Jespersgaard; K Boye; T A Brown; M Hauge; M Kilian
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

7.  Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.

Authors:  G Milan; A Zambon; M Cavinato; P Zanovello; A Rosato; D Collavo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.

Authors:  Shih-Chang Lin; Yu-Fen Lin; Pele Chong; Suh-Chin Wu
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

9.  Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope.

Authors:  Payton A Weidenbacher; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-26       Impact factor: 11.205

10.  Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.

Authors:  Wei-Shuo Lin; I-Chen Chen; Hui-Chen Chen; Yi-Chien Lee; Suh-Chin Wu
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.